Page 98 - பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் Today - Breaking & Trending Today

Germ-zapping robot maker gets new digs as business grows


Germ-zapping robot maker gets new digs as business grows
FacebookTwitterEmail
Lead Mechanical Engineer Deepak Jayaraj, left, and Xenex CEO Morris Miller, right,pose with one of the company s product, LightStrike Germ-Zapping Robots, at their new offices north of the San Antonio International Airport, Tuesday, Jan. 19, 2021. The company has sold the robots, that use UV rays to kill germs, to the San Antonio Spurs, hospitals throughout the country and the Texas State Capitol.Jerry Lara / Staff photographer
San Antonio’s disinfecting robot manufacturer, Xenex, kicked off 2021 by expanding both its facilities and its business.
With sales soaring 600 percent in 2020, due largely to the COVID-19 pandemic, the privately held firm outgrew its old space. But it found a new home in a business park two miles away, near Wurzbach Parkway and San Antonio International Airport. ....

San Antonio , United States , San Antonio International Airport , Texas State Capitol , Morris Miller , Chris Currens , Deepak Jayaraj , San Antonio Spurs , University Of Texas Md Anderson Cancer Center , Veterans Affairs , Texas State Legislature , Lead Mechanical Engineer Deepak Jayaraj , Lightstrike Germ Zapping Robots , Texas State , Jerry Lara , Staff Photographer , Antonio Express News , Wurzbach Parkway , San Antonio International , Lightstrike Robots , Strike Robots , Texas Capitol , State Preservation Board , San Antonio Express News , Cancer Center , Brandon Lingle ,

Preop RT Flunks Test in Borderline Pancreatic Cancer


This article is a collaboration between MedPage Today and:
Neoadjuvant chemoradiation failed to improve survival in borderline-resectable pancreatic cancer as compared with chemotherapy alone, a randomized trial showed.
Patients randomized to chemotherapy alone had an 18-month OS rate of 66.4% versus 47.3% for the group that received chemoradiation (CRT). A futility analysis showed that adding stereotactic body radiation therapy (SBRT) was unlikely to improve overall survival (OS).
Preoperative modified FOLFIRINOX was associated with favorable overall survival relative to historical data in patients with borderline-resectable pancreatic ductal adenocarcinoma, Matthew H.G. Katz, MD, of the University of Texas MD Anderson Cancer Center in Houston, said during the Gastrointestinal Cancers Symposium virtual meeting. We cannot conclude efficacy for modified FOLFIRINOX plus radiation, as statistical requirements were not met. ....

United States , North Carolina , Rebecca Snyder , Charles Bankhead , Matthew Hg Katz , American Society Of Clinical Oncology , University Of Texas Md Anderson Cancer Center , Medpage Today , Cancer Center , Gastrointestinal Cancers Symposium , Brody College , East Carolina University , American Society , Clinical Oncology , Carcinoma Of Pancreas , Malignant Tumor Of Pancreas , ஒன்றுபட்டது மாநிலங்களில் , வடக்கு கரோலினா , ரிபேக்க ஸ்னைடர் , சார்லஸ் வங்கித் தலை , மேத்யூ ஹ்க் க்யாட்ஸ் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , புற்றுநோய் மையம் , இரைப்பை குடல் புற்றுநோய்கள் சிம்போசியம் , பிராடி கல்லூரி ,

2021 Research Grant Recipients Announced by the VHL Alliance


2021 Research Grant Recipients Announced by the VHL Alliance
Global Research Program Supports Curing Cancer through VHL
News provided by
Share this article
Share this article
BOSTON, Jan. 19, 2021 /PRNewswire/  The VHL Alliance (VHLA) today announced the 2021 recipients of the VHLA Competitive Research Grant Program.  This year, three grantees were chosen. Scientists are increasingly aware that curing von Hippel-Lindau disease, a genetic form of cancer – is a key step to curing cancer, leading to a significant increase in the quality of research grant applicants in the program year after year. 
Over 20 top VHLA researchers from across the US, Canada, and Europe were involved in reviewing and selecting those projects which have the greatest potential to make advances toward Curing Cancer through VHL. For the second year in a row, responding to the increase in quality applications, the VHLA Board of Directors voted to expand the annual budget for resea ....

New York , United States , Tel Aviv , Amit Tirosh , David Zagzag , Chandra Clark , Eric Jonasch , Othon Iliopoulos , Heidi Leone , Division Of Cancer Medicine , Department Of Genitourinary Medical Oncology , University Of Texas Md Anderson Cancer Center , Sheba Medical Center , Competitive Research Grant , Cancer Research , Langone Medical Center , Head Of Neuroendocrine Tumors Services , Competitive Research Grant Program , Institute Of Endocrinology , Research Council , Alliance Research Council , Research Grant , Curing Cancer , Neuroendocrine Tumors Services , Genitourinary Medical Oncology , Cancer Medicine ,